Omeros | OMER - Capital Ordinário





Capital Ordinário Alterar Data
Adma Biologics USD 237.88M 457K 2025-12
Alnylam Pharmaceuticals USD 133.44M 1.07M 2026-03
BioMarin Pharmaceutical USD 193.27M 969K 2026-03
Cytokinetics USD 124.43M 2.17M 2026-03
Gilead Sciences USD 1.24B 1000K 2026-03
Heron Therapeutics USD 188.31M 4.99M 2025-12
Immunic USD 120.38M 21.73M 2025-12
Insmed USD 216.52M 2.27M 2026-03
Knight Therapeutics CAD 99.68M 24.66K 2025-09
MacroGenics USD 63.32M 60K 2025-12
Omeros USD 611K 17K 2023-12
Pacira USD 39.31M 1.81M 2026-03
Pfizer USD 5.7B 13M 2026-03
Sarepta Therapeutics USD 105.57M 607K 2026-03
United Therapeutics USD 42.16M 1.49M 2026-03
Vertex Pharmaceuticals USD 254.2M 200K 2026-03
Xoma USD 87K 1000 2024-06